



March 22, 2023

General Announcement:

Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd.

<u>Senju initiated Phase III Clinical Trials in Japan for "SJP-0132" for the treatment of Dry Eye Disease</u> <u>The Clinical Trials use a novel compound discovered by Mochida and licensed to Senju</u>

Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) and Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) are pleased to announce that Senju has started Phase III clinical trials in Japan for the novel compound discovered by Mochida and licensed to Senju (development code: SJP-0132).

Senju and Mochida previously entered into a license agreement and Senju has been developing SJP-0132, which has a novel mechanism of action, for the treatment of Dry Eye Disease.

Dry Eye Disease, the target disease of SJP-0132, is defined as "A multifactorial disease characterized by an unstable tear film causing discomfort and/or visual impairment, accompanied by ocular surface disorder". Recently, the number of Dry Eye Disease patients has been increasing due to aging, the long-term use of contact lenses, and work done using Visual Display Terminals (VDT) such as PCs and Smartphones.

Senju will work diligently toward the obtainment of Marketing Approval to provide new treatment options for patients suffering from the signs and symptoms of Dry Eye Disease.

Maximizing its foresight and originality, Mochida will be involved in research, and thus continue to contribute to improving the quality of life of patients.

"". "Dry Eye Diagnostic Guidelines" Japan Dry Eye Society (2019)

[Contact details for inquiries]

Corporate Communication Department, Senju Pharmaceutical Co., Ltd. 3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan Mail : <u>cc@senju.co.jp</u> Public Relations, Mochida Pharmaceutical Co., Ltd. 7, Yotsuya 1-chome, Shinjuku-ku,Tokyo160-8515, Japan Mail : <u>webmaster@mochida.co.jp</u> TEL : +81(0)3-3225-6303